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access provincial data is underway. The RISC continues to work 
through the NSIR-RT pilot to mitigate the identified barriers in 
an effort to improve provincially provided care. 
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CHEMORADIOTHERAPY FOR RECTAL ADENOCARCINOMA; A 
RETROSPECTIVE STUDY 
Maged Nashed1, Zachary Raizman2, Gokulan Sivananthan2, Daniel 
Kroeker2, Pascal Lambert1, Debrah Wirtzfeld2, Robert 
Wightman2 
1Cancer Care Manitoba, Winnipeg, MB 
2University of Manitoba, Winnipeg, MB 
 
Purpose: Pathological response to neoadjuvant therapy has been 
linked to long-term outcome in rectal cancer (RC). Predicting 
nodal response is important especially in cases where watch and 
wait strategy is being considered. This study was carried out to 
identify potential predictors of pathological nodal response after 
long course chemoradiotherapy (CRT). 
Methods and Materials: A retrospective review of all patients 
with clinically node positive RC who received neoadjuvant CRT 
in Manitoba between January 2007 and December 2012 was 
conducted. Pre CRT tumour staging, treatment-related 
hematologic toxicities and pathologic nodal response data were 
recorded. Univariable and Multivariable analyses were 
performed using Bayesian logistic regression models. 
Results: Two hundred and six patients with clinically node 
positive RC were included in this study. The mean number of 
excised nodes was 16.35. One hundred and seventeen patients 
(56.8%) achieved a pathologic complete nodal response. Higher 
pre-treatment carcinoembryonic antigen (CEA) level (p = 0.0072) 
and presence of lymphovascular space invasion (LVI) in the 
surgical specimen (p = 0.0002) were independent predictors of 
lack of nodal response. In the univariable analysis, there was a 
tendency to a better response in patients who developed less 
treatment-induced lymphocytopenia. 
Conclusions: Pre-treatment CEA and presence of LVI predicted 
less pathological nodal response post CRT for rectal cancer. LVI 
is a pathological finding, however, signs of vascular invasion can 
be detected on the pre-treatment MRI. These results could 
potentially be used to identify favourable responders to CRT and 
guide management strategies of rectal cancer especially when 
organ and function preservation are pursued. 
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Purpose:  Stereotactic body radiotherapy (SBRT) can treat 
hepatocellular (HCC) patients who are not eligible for surgery, 
trans-arterial chemoembolization or radiofrequency ablation. 
This study aims to compare the efficacy and toxicity of SBRT to 
small tumours (< 4.4 cm, our median population size) and 
moderate to large tumours (≥ 4.4 cm). 
Methods and Materials: A retrospective study of the first 48 
provincially treated HCC patients (March 2011-July 2015) was 
conducted. All patients were discussed at multidisciplinary 
rounds and considered ineligible for further standard local 
therapies. Local control (LC), progression free survival (PFS), 
overall survival (OS) and toxicities were analyzed. 
Results: Fifty-one separate hepatomas were treated with a 
median size of 4.4cm (range: 1.3-15.6cm). Baseline 
demographics, performance status, previous liver-directed 
treatments, and Child’s Pugh (CP) score were similar between 
the groups. Hepatitis B was more common in the ≥4.4cm group 
while Hepatitis C was more common in the < 4.4 cm group (p = 
0.05). RT doses were 36 to 50 Gy in three to 10 fractions, with 
87% of patients receiving 45 Gy in 3 or 5 fractions. Twenty-eight 
(55%) hepatomas were treated with a biological equivalent dose 
(BED10) ≥ 100 Gy and 45 (88.3%) were treated with a BED10 ≥ 80 
Gy. Tumours <4.4cm were more likely to be treated with a BED10 
≥ 80 Gy (p < 0.001). Seven patients (15%) had worsened CP score 
by > 1 point at three months post-SBRT, but this was not different 
between the two groups (p = 0.86). LC for all patients was 94% 
at one and two years, and was comparable for tumours < 4.4 cm 
and ≥ 4.4 cm (two year LC: 96% for < 4.4 cm versus 92% for ≥ 4.4 
cm, p = 0.91). OS for all patients was 65% at two years (87% for 
< 4.4 cm versus 46% for ≥ 4.4 cm, p = 0.07). PFS was 38% at two 
years for all patients, and did not differ significantly between 
groups (p = 0.70). On univariate analysis, BED10 ≥ 80 Gy was the 
only factor associated with improved PFS, while both BED10 ≥ 80 
Gy and normal baseline AFP were associated with improved OS. 
Conclusions: SBRT provides high local control for patients with 
inoperable HCC and can be delivered with acceptable risk for 
post-treatment hepatic injury even for moderate to large sized 
tumours. Radiation doses above BED10 of 80 Gy improved PFS 
and OS in our cohort. 
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Purpose: Concurrent chemoradiation (CRT) with fluorouracil (5-
FU) and mitomycin C (MMC) is standard treatment for anal canal 
carcinoma (ACC). However, treatment varies based on available 
RT technology and centre preference for chemotherapy (CT) 
regimen. The purpose of this study was to compare dosimetric 
parameters, toxicity, and outcomes in ACC patients treated with 
two different RT modalities and CT regimens. 
Methods and Materials: This is a retrospective study of 
consecutive ACC patients treated with radical CRT at two 
tertiary cancer centres from 2008-2012. Patients were grouped 
according to RT modality (IMRT versus HT), and CT regimen (5-
FU with: one cycle MMC, MMC1 versus two cycles, MMC2). 
Primary endpoints were dosimetric comparison between the RT 
cohorts and toxicity comparison between the CT cohorts; 
secondary endpoint was comparison of outcomes, including 
patterns of failure, disease-free survival (DFS), overall survival 
(OS), colostomy-free survival (CFS). 
Results: Of 64 patients in total, 34 (53%) were treated with IMRT 
and 30 (47%) with HT. Patient and tumour characteristics were 
not significantly different between the groups. Twenty-six 
patients (43%) received MMC1, while 34 (57%) patients received 
MMC2; 4 patients received 5FU/cisplatin. The majority (25/34, 
74%) of IMRT patients received MMC1, while most HT patients 
(29/30, 97%) received MMC2 (p < 0.01), which correlated with 
treatment centre. HT achieved more homogenous coverage of 
the primary tumour (HT homogeneity and uniformity index 0.15 
and 1.03 versus 0.29 and 1.06 for IMRT, p < 0.01 and p < 0.01). 
IMRT achieved better bladder, femoral head and peritoneal 
space sparing, and lower skin dose (p < 0.01 for all). HT achieved 
lower bone marrow and external genitalia dose (both p < 0.01) 
versus IMRT. Comparing CT regimens, MMC2 was more strongly 
associated with Grade 2+ neutropenia (p = 0.03) and Grade 4 
toxicity (p = 0.03) versus MMC1. There were no differences in 
local, regional or distant failure based on RT modality (p = 0.46, 
p = 0.62, p = 0.12, respectively) or CT regimen (p = 1.0, p = 0.31, 
p = 0.16). Additionally, there were no differences in OS, DFS or 
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CFS by RT modality (p = 0.62, p = 0.87, p = 0.76) or CT regimen 
(p = 0.94, p = 0.78, p = 0.90). 
Conclusions: IMRT and HT differ with respect to dose 
homogeneity and normal-tissue sparing. Acute toxicity was 
significantly increased in patients receiving MMC2 compared to 
MMC1. However, there were no differences in outcome based on 
either RT modality or chemotherapeutic regimen between these 
cohorts. 
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Purpose: Image-guided, intensity-modulated radiation therapy 
(IG-IMRT) allows accurate, conformal treatment of the prostate 
bed post-prostatectomy. However, a large planning target 
volume (PTV) is still required to address deformations due to 
variations in rectum and bladder filling. Adaptive radiation 
therapy is a potential solution that has not been explored in this 
setting. We present the results of a feasibility study of ART for 
post-prostatectomy prostate cancer. 
Material and Methods: Twenty-one patients were initially 
planned and treated with IG-IMRT according to our institutional 
standard. The original clinical target volume, plus the CTV that 
was recontoured on cone-beam CT (CBCT) images from the first 
four fractions and used to create an adapted PTV. A new plan 
using the adapted PTV was implemented on fraction 7 and used 
for the remaining 27 fractions. The primary study endpoint was 
improvement in dosimetric plan quality. 
Results: All patients were successfully recontoured and 
replanned within the allotted 3 day period, requiring a mean of 
1.9 days (0.4 days standard deviation). The mean adapted PTV 
volume was 19% (60 cc) smaller than the standard PTV (p < 
0.001), and smaller than standard PTV for 20 of 21 patients. 
Reconstruction of the dose delivered on 102 recontoured weekly 
CBCT following adaptation shows the mean CTV coverage is 
similar although slightly lower in ART plans (mean CTV D99 94% 
[1%]) compared to if the unadapted standard plans had been 
continued (96% [1%]) (p < 0.001). Reconstructed small bowel dose 
demonstrated fewer fractions of the ART plan with small bowel 
exceeding 75% of the prescription dose (11% ART fractions versus 
18% standard, p < 0.01). 
Conclusions: ART for post-prostatectomy prostate cancer is 
feasible and safe, facilitates PTV volume reduction while 
maintaining reasonable CTV coverage, and can reduce the dose 
to adjacent normal tissues. 
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Purpose: Metastatic renal cell carcinoma (mRCC) represents one 
of the few end-stage malignancies where aggressive treatment 
to the primary tumour (i.e. cytoreductive nephrectomy) is 
associated with a survival benefit. Criteria published by (Heng et 
al. 2009) have assisted in the risk-stratification of patients who 
may benefit most from this, but many are not surgical candidates 
due to medical inoperability or unresectable disease. We 
hypothesized that SABR could serve as a safe alternative 
modality for such patients. Our study objectives were to report 
on technical considerations, toxicity, and outcomes of our 
institutional experience with SABR for large renal tumours. 
Methods and Materials: In this research ethics board approved 
study, a retrospective review of patient databases was 
conducted to identify patients with RCC (presumed or biopsy-
confirmed) who underwent SABR at our institution between 
January 2008 and June 2015. Clinical and dosimetric data were 
abstracted from electronic and paper records. Toxicity was 
quantified using the CTCAE v4.0 and the RECIST classification 
was used to evaluate radiographic response. Median overall 
survival and follow up were calculated using the Kaplan-Meier 
and reverse Kaplan-Meier methods, respectively. 
Results: We identified 11 patients of median age 79 (range 61-
87), the majority (n = 9) with Stage III-IV disease. Patients were 
classified as poor (n = 5) or intermediate (n = 4) risk based on the 
model by Heng et al. SABR was directed to the tumour alone (n 
= 7) or the whole kidney (n = 4). Median tumour size, GTV, and 
PTV were 9.5 cm (range: 7.5-24.4), 482.6 cm3 (range: 185.7 – 
4617.8), and 819.3 cm3 (range: 313.4 – 5704.3), respectively. 
SABR was delivered in five fractions to a dose of 25 (n = 6), 30 (n 
= 3), 35 (n = 1), or 40 Gy (n = 1). Favourable coverage of 
treatment volumes and largely acceptable doses to organs at risk 
were achieved via IMRT (n = 6), Helical Tomotherapy (n = 3), or 
VMAT (n = 2). Median follow up was 12.9 months (95% confidence 
interval [CI]: 1.3 – 56.1). Five cases of CTCAE Grade 1 toxicities 
were reported. Grade 2 diarrhea and probable Grade 3 nausea 
were observed in one patient with the largest tumour treated in 
the study. In patients with follow up imaging (n = 7), SABR 
resulted in stable disease (n = 5), partial response (n = 1), or 
progressive disease (n = 1). Median overall survival was 20.4 
months (95% CI: 4.24 – N/A) 
Conclusions: SABR can be delivered safely and with minimal 
toxicity, as demonstrated in this small retrospective cohort of 
patients with large primary renal tumours. A Phase I study at our 
institution is currently underway to prospectively determine 
maximum tolerable and optimal dosing in this setting 
(NCT02264548). 
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LOW BASELINE TESTOSTERONE IS A PROGNOSTIC FACTOR IN 
RADIOTHERAPY FOR PROSTATE CANCER  
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Purpose: Low baseline testosterone level is a known adverse 
prognostic factor in patients treated with prostatectomy and a 
positive predictive factor in patients treated for metastases or 
recurrences. Little is known about its importance in radiotherapy 
for localized prostate cancer. 
Methods and Materials: Patients treated at our institution in 
prospective Phase 2 or 3 clinical trials and who had a baseline 
total testosterone level available before initiation of any 
treatment were selected from our institutional database. All 
patients received between 70-79.2 Gy in 1.8-2 Gy per fraction or 
a biological equivalent dose in hypofractionated protocols. A 
total testosterone (TT) level of < 10.4 nmol/L (< 300 ng/dL) was 
chosen as a cut-off, this being often used to define low TT levels. 
Results: A total of 360 patients were identified. Of these, 71% 
had D’Amico low- or intermediate-risk cancers, the remainder 
having high-risk cancers. Fifty-eight percent were > 70 years old 
and 29% had a BMI > 30 kg/m2 (BMI data was available in 76% of 
the patients). Median follow up was 67 months (IQR 40-90 
months). Baseline TT level was < 10.4 nmol/L in 58% of patients. 
Sixty-four patients (18%) experienced biochemical recurrence 
(BCR). Median time to BCR was 57 months (range 5-112 months). 
Fifty-five patients died at a median of 64 months after treatment 
(IQR 36-80 months). Testosterone as a continuous variable was 
not correlated to age (p = 0.27) and only weakly inversely 
correlated to BMI (r=-0.16, p = 0.009). On univariate analysis, 
patients with a TT< 10.4 nmol/L value had significantly lower 
rate of BCR (p = 0.044). This effect was maintained on 
